Web5 feb. 2024 · IFCT-1601 IONESCO (NCT03030131) and PRINCEPS (NCT02994576) assessed the PD-L1 inhibitors durvalumab (Imfinzi) and atezolizumab (Tecentriq), … Web#ESMO20 Study design of IoNESCO IFCT-1601: included stage IB, II, IIIA (non-N2), treatment was three doses of durvalumab every 2 weeks followed by surgery within 2-14d of resection. Primary endpoint was feasibility of resection with 90d mortality as a secondary. #LCSM @OncoAlert
Neoadjuvant durvalumab for resectable non-small-cell lung
Web1214O - Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO) Presenter: Marie Wislez Session: Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies Resources: Abstract Slides Webcast 19 Sep 2024 WebNeoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): preliminary results from a multicenter study (IFCT-1601 IONESCO). Ann Oncol. 2024; 31 ( [abstract 1214O] ) : S794 Abstract tiyan weather radar
Despite High Post-Surgical Mortality, Promising Responses …
WebSYNOPSIS DE L’ESSAI IFCT-1601 IONESCO IFCT-1601 IONESCO Synopsis v1.4 08/01/2024 1/5 Code IFCT-1601 IONESCO N° Eudract 2016-001849-15 Investigateur Coordinateur Pr Marie Wislez Service de Pneumologie Hôpital Tenon 4 rue de la Chine 75970 PARIS CEDEX 20 Email : [email protected] Web14 mrt. 2024 · Résultats de l'étude IFCT-1601 IONESCO publiés dans J Immunother Cancer En savoir plus Rigueur scientifique et transparence des groupes coopérateurs : la dynamique française Publication : 12 octobre 2024 En savoir plus IFCT-1701 DICIPLE Publication : 19 septembre 2024 Retour en vidéo sur les résultats présentés à l'ESMO … WebThe IFCT-1601 IONESCO trial showed for the first time that the extent of pathological response to a neoadjuvant immune checkpoint inhibitor is an independent prognostic … tiyan teaser in the great fathe movies